 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Viragen, Inc.
 |
Viragen, Inc. |
 |
 |
 |
PROFILE |
 |
Viragen is no buttinsky. The development-stage company works with human interferons, which it hopes to use to treat cancer (particularly melanoma), AIDS, hepatitis B and C, and multiple sclerosis. Produced in white blood cells, interferons interfere with the growth of malignant cancer cells and such foreign substances as viruses. Viragen has developed but not yet received FDA or European Union approval for Omniferon, an injectable form of human interferon. The company has white blood cell supply agreements with The American Red Cross, America's Blood Centers, the Scottish National Blood Transfusion Service, and German Red Cross blood blanks. Viragen conducts the majority of its research in Scotland.
COMPETITION |
 |
Genentech, Inc. (DNA)
GlaxoSmithKline plc (GSK)
Schering-Plough Corporation (SGP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (75.0)%
Employees: 42
Revenue per employee: $2,380.95
KEY PEOPLE |
 |
Gerald Smith
CEO
Dennis W. Healey
CFO
CONTACT INFO |
 |
865 SW 78th Ave., Ste. 100
Plantation, FL 33324
US
Phone: 954-233-8746
Fax: 954-233-1414
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |